

Leukemia & Lymphoma Society



1311 Mamaroneck Avenue, Suite
310
White Plains, NY 10605
(914) 949-5213
www.lls.org



Mission

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma, and improve the quality of life of patients and their families.

Strategy/Approach

LLS is the world's largest voluntary health agency dedicated to blood cancer. It funds blood cancer research around the world and provides free information and support services to patients and their loved ones. LLS'S priorities are:

Research

- Advance the diagnosis and treatment of blood cancers through continued funding of academic research, the Therapy Acceleration Program, and other special initiatives
- Proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma, and myeloma
- Participate directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists

Patient Services

- Develop a services agenda for patients and their families to address their information and support needs
- Inform blood cancer patients and improve access to the latest individual therapy options and blood cancer clinical trials
- LLS is the key source of information and services for patients throughout their cancer journey

Public Policy

- Increase funding for blood cancer research from non-LLS sources and accelerate the development of blood cancer therapies
- Encourage an effective and science-driven regulatory system for efficient review of new blood cancer therapies
- Ensure patients have insurance coverage for their treatments and well-coordinated and high-quality cancer care

Research Portfolio

- **Grants:** LLS supports the world's best and brightest academic researchers providing funding across the continuum, from basic and translational research through clinical trials, from bench to bedside. LLS has a variety of academic grants programs, from those supporting early and mid-career researchers, those supporting large collaborative teams of researchers,

and those accelerating the movement of promising discoveries from the lab to the clinic.

- **The Therapy Acceleration Program** – The Therapy Acceleration Program (TAP) at LLS is a strategic initiative to speed the development of blood cancer treatments and supportive diagnostics. TAP looks to fund projects related to therapies that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need. The program comprises three divisions: (1) Academic Concierge, (2) Biotechnology Accelerator, and (3) Clinical Trials.

Partnership Practices

LLS engages in corporate, academic, and nonprofit alliances. One recent example is:

- **Blood Cancer Research Partnership**—the LLS and Dana Farber Cancer Institute in Boston aim to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. Bringing trials closer to where patients live and are usually treated can increase trial enrollment and more rapidly advance therapies to save lives. Eleven sites have been identified for the 3-year project.

LLS also partners directly with biotechnology and pharmaceutical companies to more quickly develop potential blood cancer therapies.

Financials

LLS is a 501(c)(3) nonprofit organization. The latest financial information available is from 2012.¹

Year ending 06/30/2013:

- Revenue: \$314,315,000
- Assets: \$242,289,000
- Grants: \$58,899,000
- Expenditures: \$327,606,000

Key Accomplishments

- Funded nearly 400 cutting-edge research projects worldwide.
- In 2013, invested \$73.8 million in research, including funding 328 grants, 26 Therapy Acceleration Program partnerships, and \$6 million in direct support for pediatric indications

¹ Information obtained from LLS 2013 annual report
<http://www.lls.org/aboutlls/financialinformation/annualreports/>

- Maintains a 50-project drug development pipeline.
- Engaged in unique cross-sector partnership (The Learning Collaborative) with academia and government to translate basic discoveries into blood cancer therapies from multiple sources.
- **TAP Program** partner, Celator, announced enrollment of first patient in phase 3 clinical trials in January 2013. The drug, CPX-351, is a novel formation for older patients especially with high risk cases of acute myeloid leukemia (AML).
- Three TAP program partners, Epizyme, Onconova Therapeutics, and Acetylon Pharmaceuticals, were recognized by public markets and pharmaceutical companies during 2013 as having promising new therapies.

Leadership

The Leukemia & Lymphoma Society is governed by a **Board of Directors**, counseled by a **Medical and Scientific Advisory Board**, and managed by a New York-based **leadership staff**.

- **Interim President and CEO:** Louis J. DeGennaro, PhD, louis.degennaro@lls.org
- **Chief Development Officer:** Mark Roithmayr, mark.roithmayr@lls.org
- **Vice President for Research and Business Development:** Allison Formal